GuiYu Wang

GuiYu Wang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2023 in International Journal of Surgery
Verified
Journal Article
Open access
YLYunxiao Liu
Yunxiao Liu
YWYuliuming Wang
Yuliuming Wang
CWChunlin Wang
Chunlin Wang
XWXin Wang
Xin Wang
XZXin Zhang
Xin Zhang
GWGuiYu Wang
GuiYu Wang
Background: Robotic surgery has been a revolution for colon cancer (CC) patients, with the increasing availability of different competitive robotic systems, but evidence of relevant oncologic outcomes is indeed scarce. Our goal was to compare the surgical quality and short-term oncologic outcomes of the Kangduo Surgical Robotic System and the da Vinci Si Robotic System in patients with CC. Methods: These are results from a subcohort of a multicenter randomized controlled noninferiority trial performed in three centers in China. Enrolled patients were randomly assigned to undergo surgery using either the KD-SR-01 system (KD group) or the da Vinci Si (DV) robotic system (DV group). Neither investigators nor patients were masked to treatment allocation, but assessment of pathological outcomes was masked to treatment allocation. The primary endpoint was surgical success rate. The secondary endpoints were surgical outcomes, pathologic outcomes, and postoperative outcomes. The study is registered at www.chictr.org.cn (ChiCTR2200063172). Although the long-term follow-up results were not a predefined endpoint for this study, late-stage work is in progress. Results: A total of 58 CC patients were included in this study, 28 in the KD group and 30 in the DV group. All patients were successfully operated without any intermediate open/conventional laparoscopic surgery and the success rate of surgery was 100%. Assessment of equipment docking task load and intraoperative operating sensation score were similar between the two groups. Adverse events and Clavien–Dindo grade II or higher grade complication rates were comparable between the two groups. Device arm docking time, robotic arm operation time, and intraoperative bleeding were not significantly different between the two groups. Similar results were obtained from postoperative pathological outcomes and internal environment indexes. Conclusions: The efficacy and safety of the Kangduo Robotic Surgical System has been proved, operation of the Kangduo Robotic System by experienced surgeons for CC is not less effective than the da Vinci robotic System.

27 July 2023 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
QFQingxiao Fang
Qingxiao Fang
ZYZiming Yuan
Ziming Yuan
HHHanqing Hu
Hanqing Hu
WZWeiyuan Zhang
Weiyuan Zhang
GWGuiYu Wang
GuiYu Wang
XWXishan Wang
Xishan Wang
Background: Colorectal polyp is known a precursor of colorectal cancer (CRC) that holds an increased risk for progression to CRC. Circulating cell-free DNA (cfDNA) methylation has shown favorable performance in the detection and monitoring the malignant progression in a variety of cancers. Results: To discover cfDNA methylation markers for the diagnosis of CRC, we first performed a genome-wide analysis between eight CRC and eight polyp tissues using the Infinium HumanMethylationEPIC BeadChip. We identified 7008 DMCs, and after filtering, we validated 39 DMCs by MethylTarget sequencing in 62 CRC and 56 polyp tissues. A panel of four CpGs (cg04486886, cg06712559, cg13539460, and cg27541454) was selected as the methylation marker in tissue by LASSO and random forest models. A diagnosis prediction model was built based on the four CpGs, and the methylation diagnosis score (md-score) can effectively discriminate tissues with CRC from polyp patients (AUROC > 0.9). Finally, the cg27541454 was confirmed hypermethylated in CRC (AUC = 0.85) in the plasma validation cohort. Conclusions: Our findings suggest that the md-score could robustly detect CRC from polyp tissues, and cg27541454 may be a promising candidate noninvasive biomarker for CRC early diagnosis.

2 April 2024 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
JXJun Xiang
Jun Xiang
SLShihao Liu
Shihao Liu
ZCZewen Chang
Zewen Chang
JLJin Li
Jin Li
YLYunxiao Liu
Yunxiao Liu
GWGuiYu Wang
GuiYu Wang
Colorectal cancer (CRC) is a highly prevalent and lethal malignancy worldwide. Although immunotherapy has substantially improved CRC outcomes, intolerance remains a major concern among most patients. Considering the pivotal role of the tumor microenvironment (TME) in tumor progression and treatment outcomes, profiling the TME at the transcriptomic level can provide novel insights for developing CRC treatment strategies. Seventy-seven TME-associated signatures were acquired from previous studies. To elucidate variations in prognosis, clinical features, genomic alterations, and responses to immunotherapy in CRC, we employed a non-negative matrix factorization algorithm to categorize 2595 CRC samples of 27 microarrays from the Gene Expression Omnibus database. Three machine learning techniques were employed to identify a signature specific to immunotherapy. Subsequently, the mechanisms by which this signature interacts with TME subtypes and immunotherapy were investigated. Our findings revealed five distinct TME subtypes (TMESs; TMES1–TMES5) in CRC, each exhibiting a unique pattern of immunotherapy response. TMES1, TMES4, and TMES5 had relatively inferior outcomes, TMES2 was associated with the poorest prognosis, and TMES3 had a superior outcome. Subsequent investigations revealed that activated dendritic cells could enhance the immunotherapy response rate, with their augmentation effect closely associated with the activation of CD8+T cells. We successfully classified CRC into five TMESs, each demonstrating varying response rates to immunotherapy. Notably, the application of machine learning to identify activated dendritic cells helped elucidate the underlying mechanisms contributing to these differences. We posit that these TMESs hold promising clinical implications for prognostic evaluation and guidance of immunotherapy strategies, thereby providing valuable insights to inform clinical decision-making.

20 March 2025 in Holistic Integrative Oncology
Verified
Journal Article
Open access
PDF file
MWMeng Wang
Meng Wang
CZChaojing Zheng
Chaojing Zheng
ZWZitong Wang
Zitong Wang
RLRuifen Li
Ruifen Li
WZWeiyuan Zhang
Weiyuan Zhang
GWGuiYu Wang
GuiYu Wang
Colorectal cancer (CRC) is a highly prevalent malignancy and a leading cause of cancer-related mortality globally, necessitating the exploration of innovative diagnostic and therapeutic strategies alongside conventional approaches such as surgery, chemotherapy, and radiotherapy which exhibit inherent limitations. This review systematically examines recent advancements in CRC research, particularly focusing on early diagnostic methodologies, novel surgical techniques, advancements in radiotherapy and chemotherapy, as well as the burgeoning fields of immunotherapy and targeted therapies. A comprehensive search of the PubMed database was conducted to collate key clinical studies published over the last three years in order to assess the current landscape of CRC management. The results emphasize the paramount importance of early diagnosis and innovative surgical strategies while highlighting significant progress in radiotherapy and chemotherapy, with immunotherapy and targeted treatments emerging as promising avenues. Notably, the increasing incidence of aggressive early-onset colorectal cancer (EO-CRC) reinforces the urgent need for effective screening and prevention frameworks, supplemented by interdisciplinary treatment teams that are crucial for optimal patient management. Enhanced pathological diagnosis is vital for informing adjuvant chemotherapy decisions, and ongoing advancements in surgical methods and systemic therapies are contributing to improved patient outcomes. Furthermore, the potential of personalized cancer therapy through targeted approaches presents an exciting frontier, though further investigation is essential to better delineate candidate identification for immunotherapy. Targeted sequencing panels could play a pivotal role in optimizing patient selection for these emerging therapies, thereby augmenting CRC treatment strategies in the future.

31 August 2025 in Advanced Science
Verified
Journal Article
Open access
YLYunxiao Liu
Yunxiao Liu
LZLiwen Zhang
Liwen Zhang
YCYanfen Cui
Yanfen Cui
WZWeiyuan Zhang
Weiyuan Zhang
HHHanqing Hu
Hanqing Hu
XGXu Guan
Xu Guan
Tumor‐draining lymph nodes (LNs) immune status critically influences cancer progression and treatment response, yet reliable non‐invasive assessment remains clinically unavailable. To address this critical gap, an MRI‐derived LNs morphological and topological structure (LNs‐MTS) model is developed to evaluate the immune status of LNs in rectal cancer (RC). Integrating multicenter imaging, transcriptomic, and immunohistochemical data from 1,156 stage I‐II RC patients, enhanced immune activation in non‐metastatic LNs sized ≥0.5 cm and located ≥5 cm from the primary tumor is discovered. Then two quantitative MRI‐derived imaging features across 7,030 radiologically annotated LNs: total LNs volume (tLNV) and total LNs drainage distance (tLND) is developed, forming the basis of the LNs‐MTS model risk subtypes: high‐risk (HRS), moderate‐risk (MRS), and low‐risk (LRS). Patients in the LRS (characterized by large tLNV and distant tLND) show robust immune cell infiltration in the tumor microenvironment and excellent 5‐year survival, whereas HRS (characterized by small tLNV and near tLND) show stromal dominance and poorer prognosis. Clinically, LNs‐MTS offers a more precise and personalized risk assessment than current guideline‐based risk stratification, potentially sparing stage II‐LRS patients from unnecessary adjuvant treatment while identifying stage I‐HRS individuals for more aggressive treatment, providing valuable insights for personalized treatment strategies in RC management.

1 April 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YZYuchen Zhong
Yuchen Zhong
WZWeiyuan Zhang
Weiyuan Zhang
CZChaojing Zheng
Chaojing Zheng
HWHongyu Wu
Hongyu Wu
JLJun Luo
Jun Luo
GWGuiYu Wang
GuiYu Wang
Protein Tyrosine Phosphatase Non-Receptor Type 6 (PTPN6) plays a crucial regulatory role in cellular processes and has been implicated in oncogenesis. This pan-cancer analysis aimed to elucidate PTPN6’s involvement across various cancer types, with a particular emphasis on its association with tumor immunity. We analyzed PTPN6 expression data from open access databases using various statistical techniques, including survival analysis, genetic heterogeneity analysis, immune profiling, single-cell analysis, drug sensitivity analysis, and protein interaction analysis. We also conducted in vitro experiments utilizing colorectal cancer cell lines to validate PTPN6’s functional role. PTPN6 exhibited distinct expression patterns across cancers, and its prognostic significance was apparent in several cancer types, particularly in glioblastoma, sarcoma, and melanoma. We observed correlations between PTPN6 and immune genes/cell infiltration in these cancers, suggesting a potential role in modulating the tumor immune microenvironment. Single-cell analysis revealed that PTPN6 is predominantly localized in macrophages, B cells, and dendritic cells within the tumor microenvironment, implying its involvement in regulating immune cell function. Enrichment analysis highlighted PTPN6’s role in immune-related pathways. Drug sensitivity analysis identified specific drugs, including PAC-1, SNX-2112, BELINOSTAT, VORINOSTAT, TPCA-1, and PHA-893,888, whose efficacy may be influenced by PTPN6 expression. Knocking down PTPN6 expression inhibited the proliferation and migration of colorectal cancer cells in vitro, confirming its oncogenic role in this cancer type. This pan-cancer analysis establishes PTPN6’s multifaceted influence on tumor immunity and its potential as a biomarker and therapeutic target.